Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Autolus Therapeutics's Shareholder Yield % was -4.48%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Autolus Therapeutics Shareholder Yield % Related Terms
Autolus Therapeutics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Autolus Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6A3A vs FBRX, SGMT, EDIT: Shareholder Yield % Comparison
For the Biotechnology subindustry, Autolus Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autolus Therapeutics Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Autolus Therapeutics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Autolus Therapeutics (FRA:6A3A) has a Shareholder Yield % of -4.48% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Autolus Therapeutics and its competitors. According to the industry distribution chart, Autolus Therapeutics ranks #774 out of 1297 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Autolus Therapeutics' Shareholder Yield % too high?
Autolus Therapeutics' current Shareholder Yield % is -4.48%. Based on the distribution chart, Autolus Therapeutics ranks #774 out of 1297 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Autolus Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Shareholder Yield % compare to FBRX and SGMT?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #774 out of 1297 companies for Shareholder Yield %. This places Autolus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Autolus Therapeutics and its competitors. Autolus Therapeutics's current Shareholder Yield % is -4.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €18.17, compared to a current price of €1.32 — trading 92.7% below its estimated fair value. The current Shareholder Yield % is -4.48%. Autolus Therapeutics' overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Shareholder Yield % is -4.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?
Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued.
The current stock price of €1.32 is trading 92.7% below its estimated GF Value™ of €18.17.
GuruFocus considers Autolus Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:6A3A:
Shareholder Yield %: -4.48%
GF Value™: €18.17 vs. price of €1.32 (92.7% below fair value)
No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score
Get the complete analysis for FRA:6A3A
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6A3A has been successfully added to your 
